Liraglutide Enhances Autophagy and Promotes Pancreatic β Cell Proliferation to Ameliorate Type 2 Diabetes in High-Fat-Fed and Streptozotocin-Treated Mice
Reads0
Chats0
TLDR
Liraglutide significantly improved the symptoms of high-fat-fed and streptozotocin-induced type 2 diabetic mice, as indicated by body weight gain, reduction of blood glucose and plasma insulin, and enhanced sensitivity to insulin.Abstract:
BACKGROUND Clinical and experimental studies have revealed that liraglutide has multiple anti-diabetes biological effects. However, little is known about its role in autophagy and pancreatic β cell proliferation. This study aimed to assessed the effects of liraglutide on pancreatic b cell proliferation and autophagy in a mouse model of type 2 diabetes. MATERIAL AND METHODS The effect of liraglutide on autophagy and proliferation in pancreatic β cells was investigated using a high-fat-fed and streptozotocin-induced mouse model of type 2 diabetes. RESULTS Liraglutide significantly improved the symptoms of high-fat-fed (HFD) and streptozotocin (STZ)-induced type 2 diabetic mice, as indicated by body weight gain, reduction of blood glucose and plasma insulin, and enhanced sensitivity to insulin. The results of quantitative real-time polymerase chain reaction and Western blot analysis showed that liraglutide upregulated AGT5 expression and promoted the conversion of LC3-I to LC3-II, thus improving the defective autophagy. In addition, we observed that both mRNA and protein expressions of PCNA and Ki-67 were upregulated by liraglutide treatment. Immunocytochemical staining results showed that the number of PCNA- or Ki-67-positive cells in pancreatic islet tissues in the HFD + STZ + liraglutide group were increased compared with the HFD + STZ group. CONCLUSIONS These results strongly suggest that liraglutide is able to enhance autophagy and promote pancreatic β cell proliferation. This study improves our insights into the mechanism by which liraglutide treatment relieves diabetes, and provides experimental evidence for clinical utilization of liraglutide in type 2 diabetes treatment.read more
Citations
More filters
Journal ArticleDOI
Autophagy in metabolic disease and ageing.
Munehiro Kitada,Daisuke Koya +1 more
TL;DR: The role of autophagy in the pathogenesis of metabolic diseases associated with or occurring in the context of ageing, including insulin resistance, T2DM and sarcopenic obesity, was discussed in this article.
Journal ArticleDOI
Autophagy as an emerging target in cardiorenal metabolic disease: From pathophysiology to management
TL;DR: Accumulating evidence has recently suggested a pivotal role for proteotoxicity, the unfavorable effects of poor protein quality control, in the pathophysiology of metabolic dysregulation and related cardiovascular complications, and autophagy offers promising targets for novel strategies to prevent and treat cardiorenal metabolic diseases.
Journal ArticleDOI
Effects of newly introduced antidiabetic drugs on autophagy
TL;DR: The modulatory effects of these newly introduced antidiabetic drugs on the autophagy process are discussed and it is shown that they have shown efficacy in the management of diabetes and do not inherently cause hypoglycemia in therapeutic doses.
Journal ArticleDOI
Glucagon-Like Peptide-1 Receptor Agonist Attenuates Autophagy to Ameliorate Pulmonary Arterial Hypertension through Drp1/NOX- and Atg-5/Atg-7/Beclin-1/LC3β Pathways
Yi-Chia Wu,Wei-Ting Wang,Su-Shin Lee,Yur-Ren Kuo,Ya-Chin Wang,Shih-Jung Yen,Mei-Yueh Lee,Jwu-Lai Yeh +7 more
TL;DR: Liraglutide can mitigate the proliferation of PASMCs via inhibiting cellular Drp1/nicotinamide adenine dinucleotide phosphate (NADPH) oxidases (NOX) pathways and Atg-5/Atg-7/Beclin-1/LC3β-dependent pathways of autophagy in PAH.
Journal ArticleDOI
Gene therapy targeting cardiac phosphoinositide 3-kinase (p110α) attenuates cardiac remodeling in type 2 diabetes
Darnel Prakoso,Darnel Prakoso,Miles J. De Blasio,Miles J. De Blasio,Mitchel Tate,Mitchel Tate,Helen Kiriazis,D. Donner,Hongwei Qian,Hongwei Qian,David M Nash,Minh Deo,Kate L. Weeks,Kate L. Weeks,Laura J. Parry,Paul Gregorevic,Julie R. McMullen,Rebecca H. Ritchie +17 more
TL;DR: It is demonstrated that delayed intervention with PI3K gene therapy, administered as a single dose in mice with preexisting type 2 diabetes, attenuates several characteristics of diabetic cardiomyopathy, including diabetes-induced impairments in cardiac remodeling, oxidative stress, and function.
References
More filters
Journal ArticleDOI
Autophagy and metabolism.
TL;DR: A powerful promoter of metabolic homeostasis at both the cellular and whole-animal level, autophagy prevents degenerative diseases and does have a downside, however—cancer cells exploit it to survive in nutrient-poor tumors.
Journal ArticleDOI
Weighing Risks and Benefits of Liraglutide — The FDA's Review of a New Antidiabetic Therapy
Mary H. Parks,Curtis Rosebraugh +1 more
TL;DR: The benefits and potentially serious safety concerns associated with this new therapy, liraglutide, are discussed.
Journal ArticleDOI
Inflammation, oxidative stress, apoptosis, and autophagy in diabetes mellitus and diabetic kidney disease: the Four Horsemen of the Apocalypse.
TL;DR: In this review, the integrated mechanisms of inflammation, oxidative stress, apoptosis, and autophagy are discussed in the pathogenesis as well as progression of DM and DKD.
Journal ArticleDOI
Depression and its measurement in verbal adolescents and adults with autism spectrum disorder
TL;DR: Results suggest that cognitive-attributional symptoms of depression may be particularly prevalent in autism spectrum disorders, and validation studies of depression measures in the autism spectrum disorder population are necessary to advance research into this prevalent and impairing comorbidity.